Table 2.
Study | Design | N (Females) | Sample | Induction method | Target disorder/symptom | Outcome |
---|---|---|---|---|---|---|
Aslaksen and Lyby3 | Mixed design | 111 (76) | Healthy volunteers | Verbal information | Pain | Significantly larger nocebo hyperalgesic effect on pain report in females than in males |
Aslaksen et al4 | Within subjects design | 33 (17) | Healthy volunteers | Verbal information | Pain | Significant placebo effect on pain unpleasantness and the P2 component in the EEG in males, but not in females |
Bjørkedal and Flaten44 | Mixed design | 23 (7) | Healthy volunteers | Verbal information | Pain | Significant placebo effect on the P2 component in males, but not in females |
Aslaksen and Flaten43 | Within subjects design | 63 (32) | Healthy volunteers | Verbal information | Pain | Significant placebo effect on pain intensity in males, but not in females |
Flaten et al48 | Mixed design | 84 (47) | Healthy volunteers | Verbal information | Pain | Significant placebo effect on pain tolerance in males, but not in females |
Butcher and Carmody5 | Within subjects design | 20 (10) | Healthy volunteers | Verbal information | Pain | Significant placebo effect on pain tolerance in males, but not in females |
Krummenacher et al52 | Between-groups design | 49 (23) | Healthy volunteers (Children) | Verbal information | Pain | Placebo effect on heat pain threshold in boys and girls, but larger effect in girls compared to boys |
Theysohn et al56 | Within-subjects design | 30 (15) | Healthy volunteers | Verbal information | Pain | Placebo effect on pain report in both males and females Significantly larger placebo effect on neural modulation in males compared to females |
Colloca et al29 | Between-groups design | 109 (54) | Healthy volunteers | Verbal information | Pain | Placebo response enhanced and cortisol levels decreased significantly by vasopressin in females, but not in males |
Swider and Babel6 | Between-groups design | 84 (42) | Healthy volunteers | Conditioning | Pain | Nocebo effect in males and females, but significantly larger nocebo effect on pain report in females than in males |
Oken et al22 | Between-groups design | 40 (20) | Healthy volunteers | Verbal information | Cognitive performance | Significant placebo effect on choice reaction time in males, but not in females |
Haltia et al23 | Within-subjects design | 24 (12) | Healthy volunteers | Verbal information | Dopaminergic functioning | Significant placebo effect on reported drug effect in females, but not in males |
Kelley et al50 | Between-groups design | 289 (216) | Patients with IBS | Verbal information | IBS symptoms | Significantly larger placebo effect on IBS symptoms in females than in males |
Klosterhalfen et al24, experiment 1 | Within-subjects design | 48 (24) | Healthy volunteers | Conditioning | Nausea | Significant nocebo effect on rotation tolerance in females, but not in males |
Klosterhalfen et al24, experiment 2 | Within-subjects design | 48 (24) | Healthy volunteers | Verbal information | Nausea | Significant nocebo effect on rotation tolerance in males, but not in females |
Faasse et al47 | Between-groups design | 82 (51) | Healthy volunteers | Conditioning | Symptoms associated with intake of an inert medication (participants was informed that the medication was a beta-blocker, but in fact they received a placebo). | Significant nocebo effect on total reported symptoms and symptoms attributed to medication in females, but not in males |
Lorber et al53 | Mixed design | 86 (51) | Healthy volunteers | Conditioning | Symptoms associated with inhalation of an inert environmental toxin (participants was informed that the medication was a suspected environmental toxin, but, in fact, it was a placebo) | Significant nocebo effect on symptom report in females, but not in males |
Abrams and Kushner25 | Between-groups design | 41 (25) | Participants were diagnosed with social phobia | Verbal information | Mental distress, fear of negative evaluation | Significant placebo effect on mental distress in males only |
Abbreviations: EEG, electroencephalogram; IBS, irritable bowel syndrome